Cullinan Therapeutics Inc News - CGEM | ADVFN

Register for real-time alerts, custom portfolio, and market movers

Get Started

Home
Investing
Stocks
USA
NASDAQ
Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (CGEM) News

Cullinan Therapeutics Inc (CGEM)

20.13

0.22

(1.10%)

At close: July 26 4:00PM

Delayed by 15 minutes

20.16

0.03

( 0.15% )

After Hours: 4:05PM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today...

Current Report Filing (8-k)

false 0001789972 0001789972 2022-06-22 2022-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

Cullinan Oncology receives upfront cash payment of $275 million, with potential to receive up to an additional...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today...

H.C. Wainwright Thinks Cullinan Management’s Stock is Going to Recover

H.C. Wainwright analyst Edward White maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of...

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

Updated data from Phase 1/2a study show median duration of response greater than 21 months and median...

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE...

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a...

H.C. Wainwright Thinks Cullinan Management’s Stock is Going to Recover

H.C. Wainwright analyst Edward White reiterated a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of...

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated...

Monksdream

Monksdream 3 months ago

CGEM new 52 week high

Cullinan Therapeutics

Delayed Upgrade Clock